Therapeutic rationale for targeted IL-36 receptor inhibition

The progress in the diagnosis and treatment of generalized pustular psoriasis (GPP) is remarkable. GPP has developed into a clearly defined, independent, IL-36-mediated autoinflammatory disease. Today, the high chronic disease burden far beyond the acute flare-ups is recognized. With the introduction of IL-36 receptor inhibitors, a highly effective, rapid onset, pathophysiology-based therapy is available for the first time.